Ultragenyx to Participate in Investor Conferences in December
Ultragenyx to Participate in Investor Conferences in December
NOVATO, Calif., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultrarare genetic diseases, today announced participation in three upcoming investor conferences.
加利福尼亞州諾瓦託，2024年11月26日(GLOBE NEWSWIRE) -- ultragenyx pharmaceutical公司(NASDAQ: RARE)，一家專注於開發和商業化罕見和超罕見遺傳病新療法的生物製藥公司，今天宣佈將參加三個即將舉行的投資者會議。
Citi's 2024 Global Healthcare Conference (Miami, FL)
花旗銀行2024全球醫療保健會議(邁阿密，佛羅里達州)
- Tuesday, December 3, 2024, Emil Kakkis, M.D., Ph.D., CEO and President and Howard Horn, Chief Financial Officer, will participate in a fireside chat and host 1x1 meetings.
- 2024年12月3日星期二，首席執行官和總裁Emil Kakkis萬.D.博士以及首席財務官Howard Horn將參加爐邊聊天，並舉行1x1會議。
7th Annual Evercore ISI HealthCONx Conference (Coral Gables, FL)
第七屆年度evercore ISI HealthCONx會議(科勒蓋布爾斯，佛羅里達州)
- Wednesday, December 4, 2024, Emil Kakkis and Howard Horn will participate in a fireside chat and host 1x1 meetings.
- 2024年12月4日星期三，Emil Kakkis和Howard Horn將參加爐邊聊天，並舉行1x1會議。
Piper Sandler's 36th Annual Healthcare Conference (New York, NY)
派傑投資第36屆醫療會議(紐約，紐約)
- Thursday, December 5, 2024, Eric Crombez, M.D., Chief Medical Officer and Howard Horn will participate in a fireside chat and host 1x1 meetings.
- 週四，2024年12月5日，首席醫療官Eric Crombez博士和霍華德·霍恩將參加爐邊聊天，並舉行1x1會議。
The live and archived webcast of the fireside chats will be accessible from the company's website at
爐邊聊天的現場直播和存檔將可從該公司網站訪問。
About Ultragenyx Pharmaceutical Inc.
關於Ultragenyx Pharmaceutical Inc.
Ultragenyx is a biopharmaceutical company committed to bringing novel products to patients for the treatment of serious rare and ultrarare genetic diseases. The company has built a diverse portfolio of approved therapies and product candidates aimed at addressing diseases with high unmet medical need and clear biology for treatment, for which there are typically no approved therapies treating the underlying disease.
Ultragenyx是一家生物製藥公司，致力於爲罕見的和極其罕見的遺傳病提供新型治療產品。該公司已構建了一個多樣化的批准治療方案和產品候選組合，旨在解決存在高需求和明確生物學治療的疾病，而通常沒有治療相關潛在疾病的批准治療方案。
The company is led by a management team experienced in the development and commercialization of rare disease therapeutics. Ultragenyx's strategy is predicated upon time- and cost-efficient drug development, with the goal of delivering safe and effective therapies to patients with the utmost urgency.
該公司由一支有豐富罕見病治療藥物開發和商業化經驗的管理團隊領導。Ultragenyx 的策略基於及時高效的藥品研發，旨在以最大的緊迫性向患者提供安全有效的治療。
For more information on Ultragenyx, please visit the company's website at: .
有關Ultragenyx的更多信息，請訪問該公司的網站。
Contacts – Ultragenyx Pharmaceutical, Inc.
聯繫方式-醫療保健-Ultragenyx Pharmaceutical, Inc.
Investors
Joshua Higa
ir@ultragenyx.com
投資者
Joshua Higa
ir@ultragenyx.com
譯文內容由第三人軟體翻譯。
